BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.95B | 2.85B | 2.75B | 2.59B | 2.47B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.95B | 2.85B | 2.75B | 2.59B | 2.47B |
| Cost of Revenue | 949.13M | 969.01M | 970.80M | 910.38M | 904.12M |
| Gross Profit | 2.00B | 1.88B | 1.78B | 1.68B | 1.57B |
| SG&A Expenses | 854.38M | 874.17M | 962.90M | 925.19M | 907.29M |
| Depreciation & Amortization | 33.81M | 43.26M | 48.84M | 59.51M | 60.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.20B | 2.24B | 2.37B | 2.29B | 2.27B |
| Operating Income | 754.50M | 609.07M | 379.11M | 295.75M | 201.83M |
| Income Before Tax | 674.31M | 541.76M | 391.45M | 298.68M | 237.35M |
| Income Tax Expenses | 150.42M | 114.90M | 69.16M | 42.09M | 31.90M |
| Earnings from Continuing Operations | 523.88 | 426.86 | 322.29 | 256.59 | 205.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 523.88M | 426.86M | 322.29M | 256.59M | 205.46M |
| EBIT | 754.50M | 609.07M | 379.11M | 295.75M | 201.83M |
| EBITDA | 845.65M | 705.50M | 478.79M | 402.10M | 307.15M |
| EPS Basic | 2.75 | 2.25 | 1.70 | 1.36 | 1.09 |
| Normalized Basic EPS | 2.65 | 2.19 | 1.38 | 1.08 | 0.75 |
| EPS Diluted | 2.70 | 2.20 | 1.64 | 1.30 | 1.05 |
| Normalized Diluted EPS | 2.56 | 2.10 | 1.32 | 1.03 | 0.73 |
| Average Basic Shares Outstanding | 762.20M | 760.10M | 757.89M | 755.68M | 753.51M |
| Average Diluted Shares Outstanding | 790.71M | 793.50M | 788.75M | 782.78M | 777.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |